28 results on '"Robison, Leslie L"'
Search Results
2. Dietary patterns and their associations with sociodemographic and lifestyle factors in adult survivors of childhood cancer: a cross-sectional study
- Author
-
Lan, Tuo, Wang, Mei, Ehrhardt, Matthew J, Lanctot, Jennifer Q, Jiang, Shu, Armstrong, Gregory T, Ness, Kirsten K, Hudson, Melissa M, Colditz, Graham A, Robison, Leslie L, and Park, Yikyung
- Published
- 2024
- Full Text
- View/download PDF
3. Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial
- Author
-
Armenian, Saro H, Hudson, Melissa M, Lindenfeld, Lanie, Chen, Sitong, Chow, Eric J, Colan, Steven, Collier, Willem, Su, Xiaohong, Marcus, Edward, Echevarria, Meagan, Iukuridze, Aleksi, Robison, Leslie L, Wong, F Lennie, Chen, Ming Hui, and Bhatia, Smita
- Published
- 2024
- Full Text
- View/download PDF
4. Risk of increased mortality in underweight survivors: A brief report from the Childhood Cancer Survivor Study
- Author
-
Tonorezos, Emily S., primary, Chou, Joanne F., additional, Moskowitz, Chaya S., additional, Leisenring, Wendy M., additional, Friedman, Danielle Novetsky, additional, Sklar, Charles A., additional, Dilley, Kimberly J., additional, Hudson, Melissa M., additional, Mertens, Ann, additional, Armstrong, Gregory T., additional, Robison, Leslie L., additional, Meacham, Lillian R., additional, and Oeffinger, Kevin C., additional
- Published
- 2024
- Full Text
- View/download PDF
5. Chronic Health Conditions and Longitudinal Employment in Survivors of Childhood Cancer
- Author
-
Bhatt, Neel S., primary, Goodman, Pamela, additional, Leisenring, Wendy M., additional, Armstrong, Gregory T., additional, Chow, Eric J., additional, Hudson, Melissa M., additional, Krull, Kevin R., additional, Nathan, Paul C., additional, Oeffinger, Kevin C., additional, Robison, Leslie L., additional, Kirchhoff, Anne C., additional, and Mulrooney, Daniel A., additional
- Published
- 2024
- Full Text
- View/download PDF
6. Supplementary Methods S1 from Systemic Biological Mechanisms of Neurocognitive Dysfunction in Long-Term Survivors of Childhood Hodgkin Lymphoma
- Author
-
Williams, AnnaLynn M., primary, Liu, Wei, primary, Ehrhardt, Matthew J., primary, Mirzaei Salehabadi, Sedigheh, primary, Panoskaltsis-Mortari, Angela, primary, Phillips, Nicholas S., primary, Mulrooney, Daniel A., primary, Flerlage, Jamie E., primary, Yasui, Yutaka, primary, Srivastava, Deokumar, primary, Robison, Leslie L., primary, Hudson, Melissa M., primary, Ness, Kirsten K., primary, Sabin, Noah D., primary, and Krull, Kevin R., primary
- Published
- 2024
- Full Text
- View/download PDF
7. Supplementary Table S2 from Systemic Biological Mechanisms of Neurocognitive Dysfunction in Long-Term Survivors of Childhood Hodgkin Lymphoma
- Author
-
Williams, AnnaLynn M., primary, Liu, Wei, primary, Ehrhardt, Matthew J., primary, Mirzaei Salehabadi, Sedigheh, primary, Panoskaltsis-Mortari, Angela, primary, Phillips, Nicholas S., primary, Mulrooney, Daniel A., primary, Flerlage, Jamie E., primary, Yasui, Yutaka, primary, Srivastava, Deokumar, primary, Robison, Leslie L., primary, Hudson, Melissa M., primary, Ness, Kirsten K., primary, Sabin, Noah D., primary, and Krull, Kevin R., primary
- Published
- 2024
- Full Text
- View/download PDF
8. Supplementary Figure S1 from Systemic Biological Mechanisms of Neurocognitive Dysfunction in Long-Term Survivors of Childhood Hodgkin Lymphoma
- Author
-
Williams, AnnaLynn M., primary, Liu, Wei, primary, Ehrhardt, Matthew J., primary, Mirzaei Salehabadi, Sedigheh, primary, Panoskaltsis-Mortari, Angela, primary, Phillips, Nicholas S., primary, Mulrooney, Daniel A., primary, Flerlage, Jamie E., primary, Yasui, Yutaka, primary, Srivastava, Deokumar, primary, Robison, Leslie L., primary, Hudson, Melissa M., primary, Ness, Kirsten K., primary, Sabin, Noah D., primary, and Krull, Kevin R., primary
- Published
- 2024
- Full Text
- View/download PDF
9. Exercise and QUality diet After Leukemia (EQUAL): A randomized weight loss trial among adult survivors of childhood leukemia in the Childhood Cancer Survivor Study
- Author
-
Friedman, Danielle Novetsky., primary, Chou, Joanne F., additional, Clark, Jeanne M., additional, Moskowitz, Chaya S., additional, Ford, Jennifer S., additional, Armstrong, Gregory T., additional, Mubdi, Nidha Z., additional, McDonald, Aaron, additional, Nathan, Paul C., additional, Sklar, Charles A., additional, Ramanathan, Lakshmi V., additional, Robison, Leslie L., additional, Oeffinger, Kevin C., additional, and Tonorezos, Emily S., additional
- Published
- 2024
- Full Text
- View/download PDF
10. Trans-Ancestral Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus in Survivors of Childhood Cancer
- Author
-
Im, Cindy, primary, Neupane, Achal, additional, Baedke, Jessica L., additional, Lenny, Brian, additional, Delaney, Angela, additional, Dixon, Stephanie B., additional, Chow, Eric J., additional, Mostoufi-Moab, Sogol, additional, Yang, Tianzhong, additional, Richard, Melissa A., additional, Gramatges, M. Monica, additional, Lupo, Philip J., additional, Sharafeldin, Noha, additional, Bhatia, Smita, additional, Armstrong, Gregory T., additional, Hudson, Melissa M., additional, Ness, Kirsten K., additional, Robison, Leslie L., additional, Yasui, Yutaka, additional, Wilson, Carmen L., additional, and Sapkota, Yadav, additional
- Published
- 2024
- Full Text
- View/download PDF
11. St. Jude Survivorship Portal: sharing and analyzing large clinical and genomic datasets from pediatric cancer survivors
- Author
-
Matt, Gavriel Y., primary, Sioson, Edgar, additional, Shelton, Kyla, additional, Wang, Jian, additional, Lu, Congyu, additional, Zaldivar Peraza, Airen, additional, Gangwani, Karishma, additional, Paul, Robin, additional, Reilly, Colleen, additional, Acić, Aleksandar, additional, Liu, Qi, additional, Sandor, Stephanie R., additional, McLeod, Clay, additional, Patel, Jaimin, additional, Wang, Fan, additional, Im, Cindy, additional, Wang, Zhaoming, additional, Sapkota, Yadav, additional, Wilson, Carmen L., additional, Bhakta, Nickhill, additional, Ness, Kirsten K., additional, Armstrong, Gregory T., additional, Hudson, Melissa M., additional, Robison, Leslie L., additional, Zhang, Jinghui, additional, Yasui, Yutaka, additional, and Zhou, Xin, additional
- Published
- 2024
- Full Text
- View/download PDF
12. Systemic Biological Mechanisms of Neurocognitive Dysfunction in Long-Term Survivors of Childhood Hodgkin Lymphoma
- Author
-
Williams, AnnaLynn M., primary, Liu, Wei, additional, Ehrhardt, Matthew J., additional, Mirzaei Salehabadi, Sedigheh, additional, Panoskaltsis-Mortari, Angela, additional, Phillips, Nicholas S., additional, Mulrooney, Daniel A., additional, Flerlage, Jamie E., additional, Yasui, Yutaka, additional, Srivastava, Deokumar, additional, Robison, Leslie L., additional, Hudson, Melissa M., additional, Ness, Kirsten K., additional, Sabin, Noah D., additional, and Krull, Kevin R., additional
- Published
- 2024
- Full Text
- View/download PDF
13. Prediabetes and Associated Risk of Cardiovascular Events and Chronic Kidney Disease Among Adult Survivors of Childhood Cancer in the St Jude Lifetime Cohort
- Author
-
Dixon, Stephanie B., primary, Wang, Fang, additional, Lu, Lu, additional, Wilson, Carmen L., additional, Green, Daniel M., additional, Merchant, Thomas E., additional, Srivastava, Deo Kumar, additional, Delaney, Angela, additional, Howell, Rebecca M., additional, Jefferies, John L., additional, Robison, Leslie L., additional, Ness, Kirsten K., additional, Hudson, Melissa M., additional, Chemaitilly, Wassim, additional, and Armstrong, Gregory T., additional
- Published
- 2024
- Full Text
- View/download PDF
14. Severe Sepsis During Treatment for Childhood Leukemia and Sequelae Among Adult Survivors
- Author
-
Goggin, Kathryn P., primary, Lu, Lu, additional, Lee, Danielle E., additional, Howell, Carrie R., additional, Srivastava, Deokumar, additional, Brinkman, Tara M., additional, Armstrong, Gregory T., additional, Bhakta, Nickhill, additional, Robison, Leslie L., additional, Ehrhardt, Mathew J., additional, Hudson, Melissa M., additional, Krull, Kevin R., additional, Pui, Ching-Hon, additional, Rubnitz, Jeffrey, additional, Ness, Kirsten K., additional, and Wolf, Joshua, additional
- Published
- 2024
- Full Text
- View/download PDF
15. Hypogonadism and neurocognitive outcomes among childhood cancer survivors
- Author
-
Yoshida, Tomoko, primary, Alexander, Tyler, additional, Xing, Mengqi, additional, Mirzaei, Sedigheh, additional, Williams, AnnaLynn M, additional, Lubas, Margaret, additional, Brinkman, Tara M, additional, Chemaitilly, Wassim, additional, Robison, Leslie L, additional, Hudson, Melissa M, additional, Krull, Kevin R, additional, and Delaney, Angela, additional
- Published
- 2024
- Full Text
- View/download PDF
16. Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study.
- Author
-
Friedman, Danielle Novetsky, Goodman, Pamela J, Leisenring, Wendy M, Diller, Lisa R, Cohn, Susan L, Howell, Rebecca M, Smith, Susan A, Tonorezos, Emily S, Wolden, Suzanne L, Neglia, Joseph P, Ness, Kirsten K, Gibson, Todd M, Nathan, Paul C, Turcotte, Lucie M, Weil, Brent R, Robison, Leslie L, Oeffinger, Kevin C, Armstrong, Gregory T, Sklar, Charles A, and Henderson, Tara O
- Subjects
NEUROBLASTOMA ,CHILDHOOD cancer ,CANCER survivors ,STEM cell transplantation ,MORTALITY ,REGRESSION analysis - Abstract
Background Early efforts at risk-adapted therapy for neuroblastoma are predicted to result in differential late effects; the magnitude of these differences has not been well described. Methods Late mortality, subsequent malignant neoplasms (SMNs), and severe/life-threatening chronic health conditions (CHCs), graded according to CTCAE v4.03, were assessed among 5-year Childhood Cancer Survivor Study (CCSS) survivors of neuroblastoma diagnosed 1987-1999. Using age, stage at diagnosis, and treatment, survivors were classified into risk groups (low [n = 425]; intermediate [n = 252]; high [n = 245]). Standardized mortality ratios (SMRs) and standardized incidence ratios (SIRs) of SMNs were compared with matched population controls. Cox regression models estimated hazard ratios (HRs) and 95% confidence intervals for CHC compared with 1029 CCSS siblings. Results Among survivors (49.8% male; median age = 21 years, range = 7-42; median follow-up = 19.3 years, range = 5-29.9), 80% with low-risk disease were treated with surgery alone, whereas 79.1% with high-risk disease received surgery, radiation, chemotherapy ± autologous stem cell transplant (ASCT). All-cause mortality was elevated across risk groups (SMR
high = 27.7 [21.4-35.8]; SMRintermediate = 3.3 [1.7-6.5]; SMRlow = 2.8 [1.7-4.8]). SMN risk was increased among high- and intermediate-risk survivors (SIRhigh = 28.0 [18.5-42.3]; SIRintermediate = 3.7 [1.2-11.3]) but did not differ from the US population for survivors of low-risk disease. Compared with siblings, survivors had an increased risk of grade 3-5 CHCs, particularly among those with high-risk disease (HRhigh = 16.1 [11.2-23.2]; HRintermediate = 6.3 [3.8-10.5]; HRlow = 1.8 [1.1-3.1]). Conclusion Survivors of high-risk disease treated in the early days of risk stratification carry a markedly elevated burden of late recurrence, SMN, and organ-related multimorbidity, whereas survivors of low/intermediate-risk disease have a modest risk of late adverse outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
17. Plant Foods Intake and Risk of Premature Aging in Adult Survivors of Childhood Cancer in the St Jude Lifetime Cohort (SJLIFE).
- Author
-
Wang, Mei, Lan, Tuo, Williams, AnnaLynn M., Ehrhardt, Matthew J., Lanctot, Jennifer Q., Jiang, Shu, Krull, Kevin R., Armstrong, Gregory T., Hudson, Melissa M., Colditz, Graham A., Robison, Leslie L., Ness, Kirsten K., and Park, Yikyung
- Published
- 2024
- Full Text
- View/download PDF
18. Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy.
- Author
-
Ehrhardt, Matthew J., Liu, Qi, Mulrooney, Daniel A., Rhea, Isaac B., Dixon, Stephanie B., Lucas Jr, John T., Sapkota, Yadav, Shelton, Kyla, Ness, Kirsten K., Srivastava, Deo Kumar, McDonald, Aaron, Robison, Leslie L., Hudson, Melissa M., Yasui, Yutaka, and Armstrong, Gregory T.
- Published
- 2024
- Full Text
- View/download PDF
19. Dyslipidemia and cardiovascular disease among childhood cancer survivors: a St. Jude Lifetime Cohort report.
- Author
-
Goldberg, Jason F, Hyun, Geehong, Ness, Kirsten K, Dixon, Stephanie B, Towbin, Jeffrey A, Rhea, Isaac B, Ehrhardt, Matthew J, Srivastava, Deo Kumar, Mulrooney, Daniel A, Hudson, Melissa M, Robison, Leslie L, Jefferies, John L, Rohatgi, Anand, and Armstrong, Gregory T
- Subjects
DYSLIPIDEMIA ,CHILDHOOD cancer ,CARDIOVASCULAR diseases ,HDL cholesterol ,CANCER survivors ,JUVENILE diseases - Abstract
Background Childhood cancer survivors have increased risk of dyslipidemia and atherosclerotic cardiovascular disease (CVD). The aim of this study was to evaluate the prevalence and associated cardiovascular risks of specific lipid abnormalities among childhood cancer survivors. Methods Comprehensive lipid panel measurements were obtained from 4115 5-year survivors, with 3406 (mean age at evaluation = 35.2 years, SD = 10.4 years) not having previous dyslipidemia diagnosis, as well as 624 age, sex, and race and ethnicity matched community controls. Results Previously undiagnosed dyslipidemia with abnormal low-density lipoprotein (LDL) cholesterol (>160 mg/dL), non–high density lipoprotein (HDL) cholesterol (>190 mg/dL), HDL cholesterol (<40 mg/dL for men, <50 mg/dL for women), and triglycerides (>150 mg/dL) were identified in 4%, 6%, 30%, and 17%, respectively. Survivors without previous dyslipidemia diagnosis had higher LDL cholesterol and non-HDL cholesterol and lower HDL cholesterol than community controls. Cranial radiotherapy (relative risk [RR] = 2.2, 95% confidence interval [CI] = 1.6 to 3.0 for non-HDL cholesterol) and total body irradiation for hematopoietic cell transplantation (RR = 6.7, 95% CI = 3.5 to 13.0 for non-HDL cholesterol; RR = 9.9, 95% CI = 6.0 to 16.3 for triglycerides) were associated with greater risk of dyslipidemia. Diagnoses of low HDL cholesterol (hazard ratio [HR] = 2.9, 95% CI = 1.8 to 4.7) and elevated triglycerides (HR = 3.1, 95% CI = 1.9 to 5.1) were associated with increased risk for myocardial infarction, and diagnoses of high LDL cholesterol (HR = 2.2, 95% CI = 1.3 to 3.7), high non-HDL cholesterol (HR = 2.2, 95% CI = 1.3 to 3.7), low HDL cholesterol (HR = 3.9, 95% CI = 2.8 to 5.4), and elevated triglycerides (HR = 3.8, 95% CI = 2.7 to 5.5) were associated with increased risk for cardiomyopathy. Conclusions Previously undiagnosed dyslipidemia among childhood cancer survivors was associated with increased risk for myocardial infarction and cardiomyopathy. Comprehensive dyslipidemia evaluation and treatment are needed to reduce cardiovascular morbidity in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Evolving therapies, neurocognitive outcomes, and functional independence in adult survivors of childhood glioma.
- Author
-
Papini, Chiara, S., Sedigheh Mirzaei, Xing, Mengqi, Olsson, Ingrid Tonning, Blank, Peter M K de, Lange, Katharine R, Salloum, Ralph, Srivastava, Deokumar, Leisenring, Wendy M, Howell, Rebecca M, Oeffinger, Kevin C, Robison, Leslie L, Armstrong, Gregory T, Krull, Kevin R, and Brinkman, Tara M
- Subjects
GLIOMAS ,CHRONIC diseases ,RADIATION exposure ,PATH analysis (Statistics) ,MARITAL status - Abstract
Background Treatment of childhood glioma has evolved to reduce radiotherapy exposure with the goal of limiting late toxicity. However, the associations between treatment changes and neurocognition, and the contribution of neurocognition and chronic health conditions to attainment of adult independence, remain unknown. Methods Adult survivors of childhood glioma diagnosed in 1970-1999 in the Childhood Cancer Survivor Study (n = 1284; median [minimum-maximum] 30 [18-51] years of age at assessment; 22 [15-34] years from diagnosis) self-reported neurocognitive impairment and chronic health conditions. Multivariable models evaluated associations between changes in treatment exposures (surgery only, chemotherapy [with or without surgery], cranial radiation [with or without chemotherapy and/or surgery]), and neurocognitive impairment. Latent class analysis with 5 indicators (employment, independent living, assistance with routine and/or personal care needs, driver's license, marital or partner status) identified classes of functional independence. Path analysis tested associations among treatment exposures, neurocognitive impairment, chronic health conditions, and functional independence. Statistical tests were 2-sided. Results Cranial radiation exposure decreased over time (51%, 1970s; 46%, 1980s; 27%, 1990s]. However, compared with siblings, survivors with any treatment exposure were at elevated risk for neurocognitive impairment, including surgery only (eg, memory: relative risk = 2.22; task efficiency: relative risk = 1.88; both P < .001). Three classes of functional independence were identified: independent (58%), moderately independent (20%), and nonindependent (22%). Cranial radiation was associated with nonindependence through impaired task efficiency (β = 0.06), sensorimotor (β = 0.06), and endocrine (β = 0.10) chronic health conditions and through the associations between these conditions and task efficiency (each β = 0.04). Sensorimotor and endocrine chronic health conditions were associated with nonindependence through memory. Conclusion Most long-term glioma survivors achieve adult independence. However, functional nonindependence is associated with treatment-related neurocognitive impairment and chronic health conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Neurologic morbidity and functional independence in adult survivors of childhood cancer.
- Author
-
Vuotto, Stefanie C., Wang, Mingjuan, Okcu, M. Fatih, Bowers, Daniel C., Ullrich, Nicole J., Ness, Kirsten K., Li, Chenghong, Srivastava, Deo Kumar, Howell, Rebecca M., Gibson, Todd M., Leisenring, Wendy M., Oeffinger, Kevin C., Robison, Leslie L., Armstrong, Gregory T., Krull, Kevin R., and Brinkman, Tara M.
- Abstract
Objective: To examine associations between neurologic late effects and attainment of independence in adult survivors of childhood cancer treated with central nervous system (CNS)‐directed therapies. Methods: A total of 7881 survivors treated with cranial radiation therapy (n = 4051; CRT) and/or intrathecal methotrexate (n = 4193; IT MTX) ([CNS‐treated]; median age [range] = 25.5 years [18–48]; time since diagnosis = 17.7 years [6.8–30.2]) and 8039 without CNS‐directed therapy reported neurologic conditions including stroke, seizure, neurosensory deficits, focal neurologic dysfunction, and migraines/severe headaches. Functional independence was assessed using latent class analysis with multiple indicators (independent living, assistance with routine and personal care needs, ability to work/attend school, attainment of driver's license, marital/partner status). Multivariable regression models, adjusted for age, sex, race/ethnicity, and chronic health conditions, estimated odds ratios (OR) or relative risks (RR) for associations between neurologic morbidity, functional independence, and emotional distress. Results: Among CNS‐treated survivors, three classes of independence were identified: (1) moderately independent, never married, and non‐independent living (78.7%); (2) moderately independent, unable to drive (15.6%); and (3) non‐independent (5.7%). In contrast to 50% of non‐CNS‐treated survivors and 60% of siblings, a fourth fully independent class of CNS‐treated survivors was not identified. History of stroke (OR = 2.50, 95% CI: 1.70–3.68), seizure (OR = 9.70, 95% CI: 7.37–12.8), neurosensory deficits (OR = 2.67, 95% CI: 2.16–3.31), and focal neurologic dysfunction (OR = 3.05, 95% CI: 2.40–3.88) were associated with non‐independence among CNS‐treated survivors. Non‐independence was associated with emotional distress symptoms. Interpretation: CNS‐treated survivors do not attain full independence comparable to non‐CNS‐treated survivors or siblings. Interventions to promote independence may be beneficial for survivors with treatment‐related neurological sequalae. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Race and Ethnicity, Socioeconomic Factors, and Epigenetic Age Acceleration in Survivors of Childhood Cancer.
- Author
-
Chen, Cheng, Plonski, Noel-Marie, Dong, Qian, Song, Nan, Zhang, Xijun, Parikh, Hemang M., Finch, Emily R., Easton, John, Mulder, Heather L., Walker, Emily, Neale, Geoffrey, Pan, Yue, Li, Qian, Zhang, Jinghui, Krull, Kevin, Robison, Leslie L., Armstrong, Gregory T., Yasui, Yutaka, Ness, Kirsten K., and Hudson, Melissa M.
- Published
- 2024
- Full Text
- View/download PDF
23. Neurocognitive outcomes and functional independence in adult survivors of childhood medulloblastoma diagnosed over three decades.
- Author
-
Papini C, Mirzaei S S, Xing M, Tonning Olsson I, Salloum R, de Blank PMK, Lange KR, King TZ, Srivastava D, Leisenring WM, Howell RM, Oeffinger KC, Robison LL, Armstrong GT, Krull KR, and Brinkman TM
- Abstract
Background: Treatment of childhood medulloblastoma has evolved to reduce neurotoxicity while improving survival. However, the impact of evolving therapies on late neurocognitive outcomes and adult functional independence remains unknown., Methods: Adult survivors of childhood medulloblastoma (n=505; median[minimum-maximum] age, 29[18-46] years) and sibling controls (n=727; 32[18-58] years) from the Childhood Cancer Survivor Study completed surveys assessing neurocognitive problems and chronic health conditions (CHCs). Treatment exposures were categorized as historical (craniospinal irradiation [CSI]≥30 Gy, no chemotherapy), standard-risk (CSI>0 to <30 Gy +chemotherapy) and high-risk (CSI≥30 Gy +chemotherapy) therapy. Latent class analysis identified patterns of functional independence using employment, independent living, assistance with routine/personal care needs, driver's license, marital/partner status. Multivariable models estimated risk of neurocognitive impairment in survivors versus siblings and by treatment exposure group, and associations between neurocognitive impairment, CHCs, and functional independence., Results: Survivors in each treatment exposure group had 4- to 5-fold elevated risk of impaired memory and task efficiency compared to siblings. Contemporary risk-based therapies did not confer lower risk compared to historical therapy. Survivors treated in the 1990s had higher risk of memory impairment (relative risk [RR] 2.24, 95% confidence interval [CI] 1.39-3.60) compared to survivors treated in the 1970s. Sensorimotor, hearing problems and seizures were associated with 33%-34%, 25-26% and 21%-42% elevated risk of task efficiency and memory impairment, respectively. Treatment-related CHCs and neurocognitive impairment were associated with non-independence., Conclusions: Despite treatment changes, long-term survivors of childhood medulloblastoma remain at risk for neurocognitive impairment, which was associated with CHCs. Neurocognitive surveillance after contemporary regimens is imperative., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
24. Using Neurocognitive Phenotypes to Inform Interventions for Adult Survivors of Childhood Cancer.
- Author
-
Banerjee P, Phillips NS, Liu W, Ehrhardt MJ, Bhakta N, Brinkman TM, Williams AM, Yasui Y, Khan RB, Srivastava D, Ness KK, Robison LL, Hudson MM, and Krull KR
- Abstract
Background: Neurocognitive impairments are sequelae of childhood cancer treatment, however little guidance is given to clinicians on common phenotypes of impairment, or modifiable risk factors that could lead to personalized interventions in survivorship., Methods: Standardized clinical testing of neurocognitive function was conducted in 2,958 (74.1%) eligible survivors, who were ≥5 years post-diagnosis and >18 years old, and 477 community controls. Impairment was examined across 20 measures and phenotypes were determined by latent class analysis. Multinomial logistic regression was used to estimate risk for phenotype, predicted by cancer diagnosis and treatment exposures, chronic health conditions, and lifestyle, adjusted for sex and age. Associations between phenotypes and social attainment were examined., Results: Five neurocognitive phenotypes were identified in survivors (global impairment 3.7%, impaired attention 5.0%, memory impairment 7.2%, processing speed/executive function impairment 9.3%, no impairment 74.8%). Risk of global impairment was associated with severe chronic health condition burden (odds ratio [OR]=20.17, 95% confidence interval [95%CI] 11.41-35.63) including cerebrovascular disease (OR = 14.5, 95%CI = 5.47-38.44) and cerebrovascular accident (OR = 14.7, 95%CI = 7.50-26.40). Modifiable risk factors, like quitting smoking reduced risk for global impairment (OR = 0.21, 95%CI 0.06-0.66). Low physical activity increased risk for global impairment (OR = 4.54, 95%CI 2.86-7.21), attention impairment (OR 2.01, 95%CI 1.41-2.87), processing speed/executive function impairment (OR 1.90, 95%CI 1.46-2.48), and memory impairment (OR 2.09, 95%CI 1.54-2.82)., Conclusions: Results support the clinical utility of neurocognitive phenotyping to develop risk profiles and personalized clinical interventions, such as preventing cerebrovascular disease in anthracycline treated survivors by preventing hypercholesterolemia, smoking, and sedentary lifestyle, to reduce the risk for global impairment., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
25. Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study.
- Author
-
Friedman DN, Goodman PJ, Leisenring WM, Diller LR, Cohn SL, Howell RM, Smith SA, Tonorezos ES, Wolden SL, Neglia JP, Ness KK, Gibson TM, Nathan PC, Turcotte LM, Weil BR, Robison LL, Oeffinger KC, Armstrong GT, Sklar CA, and Henderson TO
- Subjects
- Humans, Male, Female, Child, Adolescent, Adult, Young Adult, Neoplasms, Second Primary epidemiology, Neoplasms, Second Primary mortality, Risk Factors, United States epidemiology, Proportional Hazards Models, Incidence, Child, Preschool, Neuroblastoma mortality, Neuroblastoma therapy, Cancer Survivors statistics & numerical data
- Abstract
Background: Early efforts at risk-adapted therapy for neuroblastoma are predicted to result in differential late effects; the magnitude of these differences has not been well described., Methods: Late mortality, subsequent malignant neoplasms (SMNs), and severe/life-threatening chronic health conditions (CHCs), graded according to CTCAE v4.03, were assessed among 5-year Childhood Cancer Survivor Study (CCSS) survivors of neuroblastoma diagnosed 1987-1999. Using age, stage at diagnosis, and treatment, survivors were classified into risk groups (low [n = 425]; intermediate [n = 252]; high [n = 245]). Standardized mortality ratios (SMRs) and standardized incidence ratios (SIRs) of SMNs were compared with matched population controls. Cox regression models estimated hazard ratios (HRs) and 95% confidence intervals for CHC compared with 1029 CCSS siblings., Results: Among survivors (49.8% male; median age = 21 years, range = 7-42; median follow-up = 19.3 years, range = 5-29.9), 80% with low-risk disease were treated with surgery alone, whereas 79.1% with high-risk disease received surgery, radiation, chemotherapy ± autologous stem cell transplant (ASCT). All-cause mortality was elevated across risk groups (SMRhigh = 27.7 [21.4-35.8]; SMRintermediate = 3.3 [1.7-6.5]; SMRlow = 2.8 [1.7-4.8]). SMN risk was increased among high- and intermediate-risk survivors (SIRhigh = 28.0 [18.5-42.3]; SIRintermediate = 3.7 [1.2-11.3]) but did not differ from the US population for survivors of low-risk disease. Compared with siblings, survivors had an increased risk of grade 3-5 CHCs, particularly among those with high-risk disease (HRhigh = 16.1 [11.2-23.2]; HRintermediate = 6.3 [3.8-10.5]; HRlow = 1.8 [1.1-3.1])., Conclusion: Survivors of high-risk disease treated in the early days of risk stratification carry a markedly elevated burden of late recurrence, SMN, and organ-related multimorbidity, whereas survivors of low/intermediate-risk disease have a modest risk of late adverse outcomes., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
26. Inter-individual variation in ovarian reserve after gonadotoxic treatment in female childhood cancer survivors - a genome-wide association study: results from PanCareLIFE.
- Author
-
van der Perk MEM, Broer L, Yasui Y, Laven JSE, Robison LL, Tissing WJE, Versluys B, Bresters D, Kaspers GJL, Lambalk CB, Overbeek A, Loonen JJ, Beerendonk CCM, Byrne J, Berger C, Clemens E, van Dulmen-den Broeder E, Dirksen U, van der Pal HJ, de Vries ACH, Winther JF, Ranft A, Fosså SD, Grabow D, Muraca M, Kaiser M, Kepák T, Kruseova J, Modan-Moses D, Spix C, Zolk O, Kaatsch P, Kremer LCM, Brooke RJ, Wang F, Baedke JL, Uitterlinden AG, Bos AME, van Leeuwen FE, Ness KK, Hudson MM, van der Kooi ALF, and van den Heuvel-Eibrink MM
- Abstract
Objective: We aimed to discover new variants associated with low ovarian reserve after gonadotoxic treatment among adult female childhood cancer survivors using a genome-wide association study approach., Design: Genome-wide association study., Subjects: A discovery cohort of adult female childhood cancer survivors, from the pan-European PanCareLIFE cohort (n=743; median age: 25.8 years), excluding those who received bilateral ovarian irradiation, bilateral oophorectomy, central nerve system or total body irradiation, or stem cell transplantation. Replication was attempted in the USA-based St. Jude Lifetime Cohort (n=391; median age: 31.3 years)., Exposure: Female childhood cancer survivors are at risk of therapy-related gonadal impairment. Alkylating agents are well-established risk factors, and the inter-individual variability in gonadotoxicity may be explained by genetic polymorphisms. Data were collected in real-life conditions and cyclophosphamide equivalent dose was used to quantify alkylation agent exposure., Intervention: No intervention was performed., Main Outcome Measure: Anti-Müllerian hormone (AMH) levels served as a proxy for ovarian function and findings were combined in a meta-analysis., Results: Three genome-wide significant (<5.0x10
-8 ) and 16 genome-wide suggestive (<5.0x10-6 ) loci were associated with log-transformed AMH levels, adjusted for cyclophosphamide equivalent dose of alkylating agents, age at diagnosis, and age at study in the PanCareLIFE cohort. Based on effect allele frequency (EAF) (>0.01 if not genome-wide significant), p-value (<5.0×10-6 ), and biological relevance, 15 SNPs were selected for replication. None of the SNPs were statistically significantly associated with AMH levels. A meta-analysis indicated that rs78861946 was associated at borderline genome-wide statistical significance (Reference/effect allele: C/T; EAF: 0.04, Beta (SE): -0.484 (0.091), p-value= 9.39×10-8 )., Conclusion: This study found no genetic variants associated with a lower ovarian reserve after gonadotoxic treatment, as the findings of this GWAS were not statistically significant replicated in the replication cohort. Suggestive evidence for potential importance of one variant is briefly discussed, but the lack of statistical significance calls for larger cohort sizes. As the population of childhood cancer survivors is increasing, large-scale and systematic research is needed to identify genetic variants that could aid predictive risk models of gonadotoxicity and as well as fertility preservation options for childhood cancer survivors., (Copyright © 2024. Published by Elsevier Inc.)- Published
- 2024
- Full Text
- View/download PDF
27. Dyslipidemia and cardiovascular disease among childhood cancer survivors: a St. Jude Lifetime Cohort report.
- Author
-
Goldberg JF, Hyun G, Ness KK, Dixon SB, Towbin JA, Rhea IB, Ehrhardt MJ, Srivastava DK, Mulrooney DA, Hudson MM, Robison LL, Jefferies JL, Rohatgi A, and Armstrong GT
- Subjects
- Male, Humans, Child, Female, Cholesterol, LDL, Cholesterol, HDL, Risk Factors, Cholesterol, Triglycerides, Cardiovascular Diseases epidemiology, Cardiovascular Diseases etiology, Cancer Survivors, Neoplasms complications, Neoplasms epidemiology, Dyslipidemias etiology, Dyslipidemias complications, Myocardial Infarction complications, Cardiomyopathies complications
- Abstract
Background: Childhood cancer survivors have increased risk of dyslipidemia and atherosclerotic cardiovascular disease (CVD). The aim of this study was to evaluate the prevalence and associated cardiovascular risks of specific lipid abnormalities among childhood cancer survivors., Methods: Comprehensive lipid panel measurements were obtained from 4115 5-year survivors, with 3406 (mean age at evaluation = 35.2 years, SD = 10.4 years) not having previous dyslipidemia diagnosis, as well as 624 age, sex, and race and ethnicity matched community controls., Results: Previously undiagnosed dyslipidemia with abnormal low-density lipoprotein (LDL) cholesterol (>160 mg/dL), non-high density lipoprotein (HDL) cholesterol (>190 mg/dL), HDL cholesterol (<40 mg/dL for men, <50 mg/dL for women), and triglycerides (>150 mg/dL) were identified in 4%, 6%, 30%, and 17%, respectively. Survivors without previous dyslipidemia diagnosis had higher LDL cholesterol and non-HDL cholesterol and lower HDL cholesterol than community controls. Cranial radiotherapy (relative risk [RR] = 2.2, 95% confidence interval [CI] = 1.6 to 3.0 for non-HDL cholesterol) and total body irradiation for hematopoietic cell transplantation (RR = 6.7, 95% CI = 3.5 to 13.0 for non-HDL cholesterol; RR = 9.9, 95% CI = 6.0 to 16.3 for triglycerides) were associated with greater risk of dyslipidemia. Diagnoses of low HDL cholesterol (hazard ratio [HR] = 2.9, 95% CI = 1.8 to 4.7) and elevated triglycerides (HR = 3.1, 95% CI = 1.9 to 5.1) were associated with increased risk for myocardial infarction, and diagnoses of high LDL cholesterol (HR = 2.2, 95% CI = 1.3 to 3.7), high non-HDL cholesterol (HR = 2.2, 95% CI = 1.3 to 3.7), low HDL cholesterol (HR = 3.9, 95% CI = 2.8 to 5.4), and elevated triglycerides (HR = 3.8, 95% CI = 2.7 to 5.5) were associated with increased risk for cardiomyopathy., Conclusions: Previously undiagnosed dyslipidemia among childhood cancer survivors was associated with increased risk for myocardial infarction and cardiomyopathy. Comprehensive dyslipidemia evaluation and treatment are needed to reduce cardiovascular morbidity in this population., (© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
28. Evolving therapies, neurocognitive outcomes, and functional independence in adult survivors of childhood glioma.
- Author
-
Papini C, Mirzaei S S, Xing M, Tonning Olsson I, de Blank PMK, Lange KR, Salloum R, Srivastava D, Leisenring WM, Howell RM, Oeffinger KC, Robison LL, Armstrong GT, Krull KR, and Brinkman TM
- Subjects
- Adult, Humans, Survivors, Outcome Assessment, Health Care, Employment, Functional Status, Glioma therapy
- Abstract
Background: Treatment of childhood glioma has evolved to reduce radiotherapy exposure with the goal of limiting late toxicity. However, the associations between treatment changes and neurocognition, and the contribution of neurocognition and chronic health conditions to attainment of adult independence, remain unknown., Methods: Adult survivors of childhood glioma diagnosed in 1970-1999 in the Childhood Cancer Survivor Study (n = 1284; median [minimum-maximum] 30 [18-51] years of age at assessment; 22 [15-34] years from diagnosis) self-reported neurocognitive impairment and chronic health conditions. Multivariable models evaluated associations between changes in treatment exposures (surgery only, chemotherapy [with or without surgery], cranial radiation [with or without chemotherapy and/or surgery]), and neurocognitive impairment. Latent class analysis with 5 indicators (employment, independent living, assistance with routine and/or personal care needs, driver's license, marital or partner status) identified classes of functional independence. Path analysis tested associations among treatment exposures, neurocognitive impairment, chronic health conditions, and functional independence. Statistical tests were 2-sided., Results: Cranial radiation exposure decreased over time (51%, 1970s; 46%, 1980s; 27%, 1990s]. However, compared with siblings, survivors with any treatment exposure were at elevated risk for neurocognitive impairment, including surgery only (eg, memory: relative risk = 2.22; task efficiency: relative risk = 1.88; both P < .001). Three classes of functional independence were identified: independent (58%), moderately independent (20%), and nonindependent (22%). Cranial radiation was associated with nonindependence through impaired task efficiency (β = 0.06), sensorimotor (β = 0.06), and endocrine (β = 0.10) chronic health conditions and through the associations between these conditions and task efficiency (each β = 0.04). Sensorimotor and endocrine chronic health conditions were associated with nonindependence through memory., Conclusion: Most long-term glioma survivors achieve adult independence. However, functional nonindependence is associated with treatment-related neurocognitive impairment and chronic health conditions., (© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.